U.S., Nov. 7 -- ClinicalTrials.gov registry received information related to the study (NCT07920887) titled 'A Study of Bimagrumab in Participants With HFpEF' on Oct. 29.
Brief Summary: This study will look at how bimagrumab affects adults who have a type of heart failure called HFpEF (heart failure with preserved ejection fraction), where the heart pumps normally but does not fill with blood as well as it should. Participation in the study will last about 76 weeks.
Study Start Date: Nov., 2026
Study Type: INTERVENTIONAL
Condition:
Heart Failure, Diastolic
Diastolic Heart Failure
Heart Failure, Normal Ejection Fraction
Heart Failure, Preserved Ejection Fraction
Intervention:
DRUG: Bimagrumab
Administered SC
DRUG: Placebo
Administer...